News

Filter

Current filters:

regorafenibStivarga

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

22-11-2012

A new targeted drug - German drug major Bayer's (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated…

BayerBiotechnologyOncologyPharmaceuticalregorafenibResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

28-09-2012

Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

COMPANY SPOTLIGHT

Menarini

Back to top